ALK-ABELLÓ NORDIC A/S

The financial health of ALK-ABELLÓ NORDIC A/S appears to be improving, with a notable increase in revenue and profit over the past year. In 2024, the company reported revenue of 590.17 million DKK and a profit of 6.8 million DKK, up from 509.67 million DKK and 3.7 million DKK in 2023. This upward trend in profitability reflects a solid growth trajectory, particularly from 2022 to 2024, where profit surged from 908,000 DKK to 6.8 million DKK. The equity position has also strengthened, rising from 10.4 million DKK in 2022 to 20.6 million DKK in 2024, indicating a healthier balance sheet. However, the company operates in a competitive pharmaceutical wholesale market, and maintaining margins will be crucial for sustaining growth.

AI-generated summary